Dopamine Hydrochloride Injection Shortage: Latest Availability and Manufacturer Updates

Source: FDA · United States

According to the U.S. Census Bureau's American Community Survey (ACS) 5-year estimates, the CDC PLACES population-level health analysis, and the CMS Hospital Compare quality data, Areazine publishes editorial articles drawing on more than 19,000 U.S. city profiles. See our methodology for full source attribution and refresh cadence.

The FDA reports an ongoing shortage of Dopamine Hydrochloride Injection, a cardiovascular medication, though several presentations remain available from Baxter Healthcare.

What this FDA drug-shortage notice tells you, and what most readers miss

This notice was issued by FDA on February 11, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken — "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to — Drug Shortages — determines the regulatory framework behind it, which shapes what remedies (refunds, replacements, recalls, evacuations) are available to affected individuals and who holds statutory responsibility for enforcement.

Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to read it as a data point about the issuing system: how quickly FDA detected the hazard, how precise the geographic or product-identifier scope is, and whether similar notices have clustered in the same category or region in the last 90 days. Cluster patterns frequently precede a broader regulatory action — a single localized FDA drug-shortage notice is isolated; three of them within a quarter often indicate a supply-chain, infrastructure, or seasonal driver that will keep producing notices until something structural changes.

For decision-making, Areazine pairs each alert with the original agency URL, the full agency name, and a timestamp so you can verify the notice against the primary source before acting on it. Tags on this item (drug-shortage, fda, medication, Dopamine Hydrochloride) map to related alerts in the same area of risk — browsing them together gives a clearer picture than any single notice alone, because the shape of an ongoing issue only becomes visible across multiple sequential alerts.

What's in Shortage

Generic Name: Dopamine Hydrochloride Injection
Brand Name: DOPAMINE HYDROCHLORIDE AND DEXTROSE
Dosage Form: Injection
Therapeutic Category: Cardiovascular
Current Status: Current Shortage
Initial Posting Date: 11/06/2017
Last Updated: 02/02/2026

Dopamine Hydrochloride Injection is currently listed as being in shortage. This medication is primarily used within the cardiovascular therapeutic category.

Which Manufacturers Are Affected

According to the FDA database, the following manufacturer information is available:

Baxter Healthcare

  • Status: Available
  • Contact Info: 888-229-0001
  • Available Presentations:
    • Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-03)
    • Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-02)
    • Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-02)
    • Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-03)

Why There's a Shortage

No specific reason for the shortage was provided in the source data at this time.

What Patients Should Do

If you are a patient or caregiver affected by this shortage, please take the following steps:

  • Consult Your Healthcare Provider: Discuss your treatment plan and any concerns regarding medication availability with your doctor.
  • Talk to Your Pharmacist: Pharmacists can provide the most current information regarding local stock and supply chain updates.
  • Contact the Manufacturer: For specific questions regarding supply, you may contact Baxter Healthcare at 888-229-0001.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients should always consult with their healthcare provider or pharmacist regarding their medications and treatment options.

Source

Attribution: FDA Drug Shortage Database

Original source: FDA Official Notice ↗

All Drug Shortages →

Frequently Asked Questions

Common questions about this FDA drug-shortage notice.

What is this FDA drug-shortage notice about?
The FDA reports an ongoing shortage of Dopamine Hydrochloride Injection, a cardiovascular medication, though several presentations remain available from Baxter Healthcare.
Which agency issued this alert?
This alert was issued by FDA. The original notice is available at the source link at the bottom of this article.
How severe is this alert?
This alert is classified as "medium" severity. Stay informed and follow agency guidance.
What area is affected?
This alert affects United States. Check with FDA for the most current geographic scope.
Where can I find more Drug Shortages updates?
Browse the full Drug Shortages feed on Areazine at areazine.com/drug-shortages/ for the latest updates from FDA and other agencies.